Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose
Authors
Minchom, A. R.Krebs, Matthew G
Cho, B. C.
Lee, S. H.
Leighl, N. B.
O'Neil, B.
Sabari, J. K.
Kudgus-Lokken, R.
Alhadab, A.
Haddish-Berhane, N.
Zemlickis, D.
Mitselos, A.
Berkay, E.
Bauml, J. M.
Knoblauch, R. E.
Hellemans, P.
Johnson, M. L.
Affiliation
Drug Development Unit at Royal Marsden Hospital/Institute of Cancer Research, SuttonIssue Date
2023
Metadata
Show full item recordCitation
Minchom AR, Krebs MG, Cho BC, Lee SH, Leighl NB, O'Neil B, et al. Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003793.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.9126Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9126Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.9126